FLIP as an Anti-Cancer Therapeutic Target

키워드

참고문헌 (84)

1. Kerr JF, "Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics", Br J Cancer, 26, pp.239~257 (1972)
2. Thome M, "Regulation of lymphocyte proliferation and death by FLIP", Nat Rev Immunol, 1, pp.50~58 (2001)
3. Wyllie AH, "Cell death: the significance of apoptosis", Int Rev Cytol, 68, pp.251~306 (1980)
4. Hanahan D, "The hallmarks of cancer", Cell, 100, pp.57~70 (2000)
5. Wajant H, "Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy", Mol Interv, 3, pp.124~127 (2003)
6. Fesik SW, "Promoting apoptosis as a strategy for cancer drug discovery", Nat Rev Cancer, 5, pp.876~885 (2005)
7. Debatin KM, "Death receptors in chemotherapy and cancer", Oncogene, 23, pp.2950~2966 (2004)
8. Reed JC, "Apoptosis-based therapies for hematologic malignancies", Blood, 106, pp.408~418 (2005)
9. Kataoka T, "The caspase-8 modulator c-FLIP", Crit Rev Immunol, 25, pp.31~58 (2005)
10. Hengartner MO, "The biochemistry of apoptosis", Nature, 407, pp.770~776 (2000)
11. Shi Y, "Caspase activation: revisiting the induced proximity model", Cell, 117, pp.855~858 (2004)
12. Muzio M, "FLICE, a novel FADD- homologous ICE", CED-3-like protease, is recruited to the CD95 (Fas, Cell, pp.1996, 85[DOI]
13. Chinnaiyan AM, "FADD", MORT1 is a common mediator of CD95 (Fas, J Biol Chem, pp.1996, 271[DOI]
14. Kischkel FC, "Cytotoxicity-dependent APO-1 (Fas", CD95)-associated proteins form a death- inducing signaling complex (DISC) with the receptor, 1995, pp.14, 5579~5588
15. Fischer U, "Many cuts to ruin: a comprehensive update of caspase substrates", Cell Death Differ, 10, pp.76~100 (2003)
16. Roos WP, "DNA damage-induced cell death by apoptosis", Trends Mol Med, 12, pp.440~450 (2006)
17. French LE, "Protein-based therapeutic approaches targeting death receptors", Cell Death Differ, 10, pp.117~123 (2003)
18. Wiley SR, "Identification and characterization of a new member of the TNF family that induces apoptosis", Immunity, 3, pp.673~682 (1995)
19. MacFarlane M, "TRAIL-induced signalling and apoptosis", Toxicol Lett, 139, pp.89~97 (2003)
20. Lahm A, "Death fold domain interaction in apoptosis", Cell Death Differ, 10, pp.10~12 (2003)
21. Thome M, "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors", Nature, 386, pp.517~521 (1997)
22. Bertin J, "Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis", Proc Natl Acad Sci U S A, 84, pp.1172~1176 (1997)
23. Hu S, "A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis", J Biol Chem, 272, pp.9621~9624 (1997)
24. Irmler M, "Inhibition of death receptor signals by cellular FLIP", Nature, 388, pp.190~195 (1997)
25. Hu S, "I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis", J Biol Chem, 272, pp.17255~17257 (1997)
26. Djerbi M, "Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms", Scand J Immunol, 54, pp.180~189 (2001)
27. Golks A, "c-FLIPR, a new regulator of death receptor-induced apoptosis", J Biol Chem, 280, pp.14507~14513 (2005)
28. Yang JK, "Crystal structure of MC159 reveals molecular mechanism of DISC assembly and FLIP inhibition", Mol Cell, 20, pp.939~949 (2005)
29. Yeh WC, "Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development", Immunity, 12, pp.633~642 (2000)
30. Goltsev YV, "CASH, a novel caspase homologue with death effector domains", J Biol Chem, 272, pp.19641~19644 (1997)
31. Han DK, "MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death", Proc Natl Acad Sci U S A, 94, pp.11333~11338 (1997)
32. Inohara N, "Núñez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis", Proc Natl Acad Sci U S A, 94, pp.10717~10722 (1997)
33. Shu HB, "Casper is a FADD- and caspase-related inducer of apoptosis", Immunity, 6, pp.751~763 (1997)
34. Chang DW, "c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis", EMBO J, 21, pp.3704~3714 (2002)
35. Kataoka T, "The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways", Curr Biol, 10, pp.640~648 (2000)
36. Hu WH, "Activation of NF-kappaB by FADD, Casper, and caspase-8", J Biol Chem, 275, pp.10838~10844 (2000)
37. Kataoka T, "N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway", Mol Cell Biol, 24, pp.2627~2636 (2004)
38. Golks A, "The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation", J Exp Med, 203, pp.1295~1305 (2006)
39. Chaudhary PM, "Activation of the NF-kappaB pathway by caspase 8 and its homologs", Oncogene, 19, pp.4451~4460 (2000)
40. Chun HJ, "Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency", Nature, 419, pp.395~399 (2002)
41. Su H, "Requirement for caspase-8 in NF-kappaB activation by antigen receptor", Science, 307, pp.1465~1468 (2005)
42. Peter ME, "The flip side of FLIP", Biochem J, 382(2), pp.e1~e3 (2004)
43. Park SJ, "Alternative splicing variants of c-FLIP transduce the differential signal through the Raf or TRAF2 in TNF-induced cell proliferation", Biochem Biophys Res Commun, 289, pp.1205~1210 (2001)
44. Li FY, "Crystal structure of a viral FLIP: insights into FLIP-mediated inhibition of death receptor signaling", J Biol Chem, 281, pp.2960~2968 (2006)
45. Eberstadt M, "NMR structure and mutagenesis of the FADD (Mort1) death-effector domain", Nature, 392, pp.941~945 (1998)
46. Huang B, "NMR structure and mutagenesis of the Fas (APO-1", CD95) death domain, 1996, pp.384, 638~341
47. Qin H, "Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1", Nature, 399, pp.549~557 (1995)
48. Tibbetts MD, "The death effector domain protein family: regulators of cellular homeostasis", Nat Immunol, 4, pp.404~409 (2003)
49. Muppidi JR, "Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis", Cell Death Differ, 13, pp.1641~1650 (2006)
50. Garvey TL, "Binding of FADD and caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function", J Virol, 76, pp.697~706 (2002)
51. Carrington PE, "The structure of FADD and its mode of interaction with procaspase-8", Mol Cell, 22, pp.599~610 (2006)
52. Hernandez A, "Sensitization of human colon cancer cells to TRAIL- mediated apoptosis", J Gastrointest Surg, 5, pp.56~65 (2001)
53. Ryu BK, "Increased expression of cFLIP(L) in colonic adenocarcinoma", J Pathol, 194, pp.15~19 (2001)
54. Korkolopoulou P, "c-FLIP expression in colorectal carcinomas: association with Fas", FasL expression and prognostic implications, 2007, pp.51, 150~156
55. Ullenhag GJ, "Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients", Clin Cancer Res, 13, pp.2070~2075 (2007)
56. Lee SH, "Increased expression of FLIP, an inhibitor of Fas- mediated apoptosis, in stomach cancer", APMIS, 111, pp.309~314 (2003)
57. Nam SY, "Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers", Cancer Sci, 94, pp.1066~1073 (2003)
58. Zhou XD, "Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma", Clin Sci (Lond), 106, pp.397~405 (2004)
59. Elnemr A, "Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway", Int J Oncol, 18, pp.311~316 (2001)
60. Mori T, "Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer", Surgery, 138, pp.71~77 (2005)
61. Thomas RK, "Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells", Am J Pathol, 160, pp.1521~1528 (2002)
62. Dutton A, "Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death", Proc Natl Acad Sci U S A, 101, pp.6611~6616 (2004)
63. Mathas S, "c-FLIP mediates resistance of Hodgkin", Reed-Sternberg cells to death receptor- induced apoptosis, 2004, pp.199, 1041~1052
64. Olsson A, "Sensitization to TRAIL- induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D", Leukemia, 15, pp.1868~1877 (2001)
65. MacFarlane M, "Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia", Oncogene, 21, pp.6809~6818 (2002)
66. Griffith TS, "Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells", J Immunol, 161, pp.2833~2840 (1998)
67. Bullani RR, "Selective expression of FLIP in malignant melanocytic skin lesions", J Invest Dermatol, 117, pp.360~364 (2001)
68. Xiao CW, "Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein", Endocrinology, 144, pp.623~630 (2003)
69. Abedini MR, "Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro", Oncogene, 23, pp.6997~7004 (2004)
70. Mezzanzanica D, "CD95-mediated apoptosis is impaired at receptor level by cellular FLICE- inhibitory protein (long form) in wild-type p53 human ovarian carcinoma", Clin Cancer Res, 10, pp.5202~5214 (2004)
71. Wang W, "The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis", Gynecol Oncol, 105, pp.571~577 (2007)
72. Korkolopoulou P, "c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations", Urology, 63, pp.1198~1204 (2004)
73. Zhang X, "Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand- mediated apoptosis in prostate cancer", Cancer Res, 64, pp.7086~7091 (2004)
74. Siegmund D, "Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis", Mol Med, 8, pp.725~732 (2002)
75. Ricci MS, "Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity", Mol Cell Biol, 24, pp.8541~8555 (2004)
76. Kim K, "Molecular determinants of response to TRAIL in killing of normal and cancer cells", Clin Cancer Res, 6, pp.335~346 (2000)
77. Djerbi M, "The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors", J Exp Med, 190, pp.1025~1032 (1999)
78. Ashkenazi A, "Safety and antitumor activity of recombinant soluble Apo2 ligand", J Clin Invest, 104, pp.155~162 (1999)
79. Walczak H, "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo", Nat Med, 5, pp.157~163 (1999)
80. Arkin M, "Protein-protein interactions and cancer: small molecules going in for the kill", Curr Opin Chem Biol, 9, pp.317~324 (2005)
81. Sattler M, "Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis", Science, 275, pp.983~986 (1997)
82. Liu Z, "Structural basis for binding of Smac", DIABLO to the XIAP BIR3 domain, 2000, pp.408, 1004~1008
83. Wu G, "Structural basis of IAP recognition by Smac", DIABLO, 2000, pp.408, 1008~1012
84. Kussie PH, "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain", Science, 274, pp.948~953 (1996)

관련 논문AI추천